Sage Journals: Discover world-class research

Abstract

Background

Scars with poor cosmesis that develop after wound healing may affect normal life.

Objective

To assess the efficacy and safety of botulinum toxin type A (BTXA) in preventing postoperative hypertrophic scars or keloids.

Methods

A systematic review was performed by searching the PubMed, Cochrane Library, and EMBASE databases from their inception date up to February 2020 for randomized controlled trials (RCTs) evaluating the efficacy of BTXA in preventing hypertrophic scars or keloids. The primary outcome measures included the Vancouver Scar Scale (VSS) score, Visual Analog Scale (VAS) score, scar width, patient satisfaction, and adverse events.

Results

Twelve RCTs involving 497 cases (372 patients) were included. The meta-analysis showed significant differences in the VAS score (weighted mean difference [WMD] = 1.31, 95% CI = 1.06 to 1.55, P < .00001), VSS score (WMD = −1.02, 95% CI = −1.72 to −0.32, P = .004), scar width (WMD = −0.18, 95% CI = −0.29 to −0.08, P = .0008), and patient satisfaction (relative risk = 1.25, 95% CI = 1.06-1.49, P = .01). Four studies reported trivial adverse events.

Conclusions

This meta-analysis showed that BTXA was more effective than the control treatment in preventing postoperative scars and improving the cosmetic appearance of facial scars for East Asians, and no serious adverse events were found during the follow-up period. However, there was insufficient evidence to support the use of BTXA for the prevention of scars in patients from other ethnic groups and regions or scars in non-facial areas.

Keywords

botulinum toxin type A (BTXA)scar wound healing meta‐analysis

Get full access to this article

View all access options for this article.

References

Kasyanju Carrero

LM.

W-W.

Liu

H-F.

Yin

X-F.

Zhou

B-R.

Wei‐wei.

Liu

Hou‐fang

. Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: updated review. J Cosmet Dermatol. 2019;18(1):10-15.doi:10.1111/jocd.12828

http://www.ncbi.nlm.nih.gov/pubmed/30548742

Halim

AS.

Emami

Salahshourifar

Kannan

. Keloid scarring: understanding the genetic basis, advances, and prospects. Arch Plast Surg. 2012;39(3):184-189.doi:10.5999/aps.2012.39.3.184

http://www.ncbi.nlm.nih.gov/pubmed/22783524

Wagner

. Therapy of pathological scars. J Dtsch Dermatol Ges. 2013;11(12):1139-1157.doi:10.1111/ddg.12209

http://www.ncbi.nlm.nih.gov/pubmed/24134558

Rabello

FB.

Souza

CD.

Farina Júnior

JA.

Farina

. Update on hypertrophic scar treatment. Clinics. 2014;69(8):565-573.doi:10.6061/clinics/2014(08)11

http://www.ncbi.nlm.nih.gov/pubmed/25141117

Chen

Pan

Zhang

Cheng

Tan

. The application of W-plasty combined Botox-A injection in treating sunk scar on the face. Medicine. 2018;97(30):e11427.doi:10.1097/MD.0000000000011427

http://www.ncbi.nlm.nih.gov/pubmed/30045264

Heppt

MV.

Breuninger

Reinholz

Feller-Heppt

Ruzicka

Gauglitz

. Current strategies in the treatment of scars and keloids. Facial Plast Surg. 2015;31(4):386-395.doi:10.1055/s-0035-1563694

http://www.ncbi.nlm.nih.gov/pubmed/26372714

Zhang

Lan

Ning

Jia

. Botulinum toxin type A prevents the phenotypic transformation of fibroblasts induced by TGF‑β1 via the PTEN/PI3K/AKT signaling pathway. Int J Mol Med. 2019;44(2):661-671.doi:10.3892/ijmm.2019.4226

http://www.ncbi.nlm.nih.gov/pubmed/31173164

Jeong

HS.

Lee

BH.

Sung

et al. Effect of botulinum toxin type A on differentiation of fibroblasts derived from scar tissue. Plast Reconstr Surg. 2015;136(2):171e-178e.doi:10.1097/PRS.0000000000001438

http://www.ncbi.nlm.nih.gov/pubmed/26218391

C-H.

Tseng

Y-W.

Lee

C-W

et al. Combination of mesenchymal stem cell-conditioned medium and botulinum toxin type A for treating human hypertrophic scars. J Plast Reconstr Aesthet Surg. 2020;73(3):516-527.doi:10.1016/j.bjps.2019.07.010

http://www.ncbi.nlm.nih.gov/pubmed/31488377

10.

Jablonka

EM.

Sherris

DA.

Gassner

. Botulinum toxin to minimize facial scarring. Facial Plast Surg. 2012;28(5):525-535.doi:10.1055/s-0032-1325641

http://www.ncbi.nlm.nih.gov/pubmed/23027220

11.

Haubner

Ohmann

Müller-Vogt

et al. Effects of botulinum toxin A on cytokine synthesis in a cell culture model of cutaneous scarring. Arch Facial Plast Surg. 2012;14(2):122-126.doi:10.1001/archfacial.2011.734

http://www.ncbi.nlm.nih.gov/pubmed/22006235

12.

Phillips

TJ.

Fung

Rigby

et al. The use of botulinum toxin type A in the healing of thyroidectomy wounds: a randomized, prospective, placebo-controlled study. Plast Reconstr Surg. 2019;143(2):375e-381.doi:10.1097/PRS.0000000000005264

http://www.ncbi.nlm.nih.gov/pubmed/30688903

13.

Huang

R-L.

C-K.

Tremp

Xie

Zan

. Early postoperative application of botulinum toxin type A prevents hypertrophic scarring after epicanthoplasty: a Split-Face, double-blind, randomized trial. Plast Reconstr Surg. 2019;144(4):835-844.doi:10.1097/PRS.0000000000006069

http://www.ncbi.nlm.nih.gov/pubmed/31568286

14.

Kim

SH.

Lee

SJ.

Lee

JW.

Jeong

HS.

Suh

. Clinical trial to evaluate the efficacy of botulinum toxin type A injection for reducing scars in patients with forehead laceration: a double-blinded, randomized controlled study. Medicine. 2019;98(34):e16952.doi:10.1097/MD.0000000000016952

http://www.ncbi.nlm.nih.gov/pubmed/31441893

15.

Zou

Chang

S-J

et al. Effects of botulinum toxin on improving facial surgical scars: a prospective, split-scar, double-blind, randomized controlled trial. Plast Reconstr Surg. 2018;141(3):646-650.doi:10.1097/PRS.0000000000004110

http://www.ncbi.nlm.nih.gov/pubmed/29481395

16.

Lee

SH.

Min

HJ.

Kim

YW.

Cheon

. The efficacy and safety of early postoperative botulinum toxin A injection for facial scars. Aesthetic Plast Surg. 2018;42(2):530-537.doi:10.1007/s00266-017-1008-7

http://www.ncbi.nlm.nih.gov/pubmed/29214336

17.

Y-H.

Yang

Liu

J-Q

et al. A randomized, placebo-controlled, double-blind, prospective clinical trial of botulinum toxin type A in prevention of hypertrophic scar development in median sternotomy wound. Aesthetic Plast Surg. 2018;42(5):1364-1369.doi:10.1007/s00266-018-1187-x

http://www.ncbi.nlm.nih.gov/pubmed/30019241

18.

Zelken

Yang

S-Y.

Chang

C-S

et al. Donor site aesthetic enhancement with preoperative botulinum toxin in forehead flap nasal reconstruction. Ann Plast Surg. 2016;77(5):535-538.doi:10.1097/SAP.0000000000000625

http://www.ncbi.nlm.nih.gov/pubmed/26418784

19.

Chang

C-S.

Wallace

CG.

Hsiao

Y-C.

Chang

C-J.

Chen

PK-T

. Botulinum toxin to improve results in cleft lip repair. Plast Reconstr Surg. 2014;134(3):511-516.doi:10.1097/PRS.0000000000000416

http://www.ncbi.nlm.nih.gov/pubmed/25158709

20.

Chang

C-S.

Wallace

CG.

Hsiao

Y-C.

Chang

C-J.

Chen

PK-T

. Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial. PLoS One. 2014;9(12):e115690.doi:10.1371/journal.pone.0115690

http://www.ncbi.nlm.nih.gov/pubmed/25541942

21.

Kim

YS.

Lee

HJ.

Cho

SH.

Lee

JD.

Kim

. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen. 2014;22(5):605-612.doi:10.1111/wrr.12204

http://www.ncbi.nlm.nih.gov/pubmed/24898579

22.

Ziade

Domergue

Batifol

et al. Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg. 2013;66(2):209-214.doi:10.1016/j.bjps.2012.09.012

http://www.ncbi.nlm.nih.gov/pubmed/23102873

23.

Gassner

HG.

Brissett

AE.

Otley

et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006;81(8):1023-1028.doi:10.4065/81.8.1023

http://www.ncbi.nlm.nih.gov/pubmed/16901024

24.

Berman

Maderal

Raphael

. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg. 2017;43(Suppl 1):S3-S18.doi:10.1097/DSS.0000000000000819

http://www.ncbi.nlm.nih.gov/pubmed/27347634

25.

Trisliana Perdanasari

Lazzeri

et al. Recent developments in the use of intralesional injections keloid treatment. Arch Plast Surg. 2014;41(6):620-629.doi:10.5999/aps.2014.41.6.620

http://www.ncbi.nlm.nih.gov/pubmed/25396172

26.

Ogawa

. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg. 2010;125(2):557-568.doi:10.1097/PRS.0b013e3181c82dd5

http://www.ncbi.nlm.nih.gov/pubmed/20124841

27.

Alhazmi

Aldekhayel

. The use of botulinum toxin type A to minimize scarring in cleft lip repair: a literature review. Arch Plast Surg. 2019;46(2):181-184.doi:10.5999/aps.2018.01284

http://www.ncbi.nlm.nih.gov/pubmed/30812070

28.

Arno

AI.

Gauglitz

GG.

Barret

JP.

Jeschke

. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns. 2014;40(7):1255-1266.doi:10.1016/j.burns.2014.02.011

http://www.ncbi.nlm.nih.gov/pubmed/24767715

29.

Xiao

. Effects of botulinum toxin type A on collagen deposition in hypertrophic scars. Molecules. 2012;17(2):2169-2177.doi:10.3390/molecules17022169

http://www.ncbi.nlm.nih.gov/pubmed/22354193

30.

Zhibo

Miaobo

. Potential therapeutical effects of botulinum toxin type A in keloid management. Med Hypotheses. 2008;71(4):623.doi:10.1016/j.mehy.2008.04.018

http://www.ncbi.nlm.nih.gov/pubmed/18534768

31.

Gassner

HG.

Sherris

DA.

Otley

. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg. 2000;105(6):1948-1953, 1954-1955.doi:10.1097/00006534-200005000-00005

http://www.ncbi.nlm.nih.gov/pubmed/10839391

32.

Sahinkanat

Ozkan

KU.

Ciralik

Ozturk

Resim

. Botulinum toxin-A to improve urethral wound healing: an experimental study in a rat model. Urology. 2009;73(2):405-409.doi:10.1016/j.urology.2008.07.051

http://www.ncbi.nlm.nih.gov/pubmed/18799204

33.

Lee

B-J.

Jeong

J-H.

Wang

S-G

et al. Effect of botulinum toxin type A on a rat surgical wound model. Clin Exp Otorhinolaryngol. 2009;2(1):20-27.doi:10.3342/ceo.2009.2.1.20

http://www.ncbi.nlm.nih.gov/pubmed/19434287

34.

Liu

D-Q.

X-J.

Weng

X-J

. Effect of BTXA on inhibiting hypertrophic scar formation in a rabbit ear model. Aesthetic Plast Surg. 2017;41(3):721-728.doi:10.1007/s00266-017-0803-5

http://www.ncbi.nlm.nih.gov/pubmed/28180922

35.

Prodromidou

Frountzas

Vlachos

D-EG

et al. Botulinum toxin for the prevention and healing of wound scars: a systematic review of the literature. Plast Surg. 2015;23(4):260-264.doi:10.1177/229255031502300402

http://www.ncbi.nlm.nih.gov/pubmed/26665143

36.

Kasyanju Carrero

LM.

W-W.

Liu

H-F.

Yin

X-F.

Zhou

B-R

. Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: updated review. J Cosmet Dermatol. 2019;18(1):10-15.doi:10.1111/jocd.12828

http://www.ncbi.nlm.nih.gov/pubmed/30548742

37.

Zhang

D-Z.

Liu

X-Y.

Xiao

W-L.

Y-X

. Botulinum toxin type A and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta-analysis of randomized controlled trials. PLoS One. 2016;11(3):e151627.doi:10.1371/journal.pone.0151627

http://www.ncbi.nlm.nih.gov/pubmed/26985661

38.

Wilson

. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg. 2006;117(6):1758-1766.doi:10.1097/01.prs.0000209944.45949.d1

http://www.ncbi.nlm.nih.gov/pubmed/16651948

39.

Xiao

Zhang

Cui

. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg. 2009;33(3):409-412.doi:10.1007/s00266-009-9334-z

http://www.ncbi.nlm.nih.gov/pubmed/19357910

40.

Yang

. The safety and efficacy of botulinum toxin type A injection for postoperative scar prevention: a systematic review and meta‐analysis. J Cosmet Dermatol. 2020;19(4):799-808.doi:10.1111/jocd.13139

http://www.ncbi.nlm.nih.gov/pubmed/31513335

41.

Trace

AP.

Enos

CW.

Mantel

Harvey

VM.

Keloids

HVM

. Keloids and hypertrophic scars: a spectrum of clinical challenges. Am J Clin Dermatol. 2016;17(3):201-223.doi:10.1007/s40257-016-0175-7

http://www.ncbi.nlm.nih.gov/pubmed/26894654

42.

Soltani

AM.

Francis

CS.

Motamed

et al. Hypertrophic scarring in cleft lip repair: a comparison of incidence among ethnic groups. Clin Epidemiol. 2012;4:187-191.doi:10.2147/CLEP.S31119

http://www.ncbi.nlm.nih.gov/pubmed/22879780

43.

Marston

AP.

Costello

MS.

Farhood

et al. Association of pediatric patient demographic factors and scar anatomic features with scar outcomes after surgical repair of cleft lip. JAMA Facial Plast Surg. 2019;21(5):452-457.doi:10.1001/jamafacial.2019.0669

http://www.ncbi.nlm.nih.gov/pubmed/31436786

44.

Bombaro

KM.

Engrav

LH.

Carrougher

et al. What is the prevalence of hypertrophic scarring following burns? Burns. 2003;29(4):299-302.doi:10.1016/S0305-4179(03)00067-6

http://www.ncbi.nlm.nih.gov/pubmed/12781605

45.

Glass

. Current understanding of the genetic causes of keloid formation. J Investig Dermatol Symp Proc. 2017;18(2):S50-S53.doi:10.1016/j.jisp.2016.10.024

http://www.ncbi.nlm.nih.gov/pubmed/28941494

46.

Scaglione

. Conversion ratio between Botox^®, Dysport^®, and Xeomin^® in clinical practice. Toxins. 2016;8(3):65.doi:10.3390/toxins8030065

47.

Sane

Ali

MJ.

Naik

. Comparison of safety and efficacy of Botox and Neuronox in the management of benign essential blepharospasm: a split-face study. Korean J Ophthalmol. 2019;33(5):430-435.doi:10.3341/kjo.2016.0123

http://www.ncbi.nlm.nih.gov/pubmed/31612653

48.

Costa

Pegas Pereira

ES.

de Oliveira Pereira

et al. Comparative study of the diffusion of five botulinum toxins type-A in five dosages of use: are there differences amongst the commercially-available products? Dermatol Online J. 2012;18(11):2.

http://www.ncbi.nlm.nih.gov/pubmed/23217943

49.

da Costa

Pereira

ESP.

de Oliveira Pereira

et al. Six-Month comparative analysis monitoring the progression of the largest diameter of the sweating inhibition halo of different botulinum toxins type-A. Aesthet Surg J. 2019;39(9):993-1004.doi:10.1093/asj/sjy207

http://www.ncbi.nlm.nih.gov/pubmed/30107473

50.

MK.

Cho

EB.

Park

et al. Appropriate timing of early postoperative botulinum toxin type A injection for thyroidectomy scar management: a split-scar study. Plast Reconstr Surg. 2019;144(4):659e-668.doi:10.1097/PRS.0000000000006064

http://www.ncbi.nlm.nih.gov/pubmed/31568312

51.

Gugerell

Kober

Schmid

et al. Botulinum toxin A: dose-dependent effect on reepithelialization and angiogenesis. Plast Reconstr Surg Glob Open. 2016;4(8):e837.doi:10.1097/GOX.0000000000000852

http://www.ncbi.nlm.nih.gov/pubmed/27622105

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.06 MB

0.00 MB

Efficacy and Safety of Botulinum Toxin Type A in Preventing Postoperative Scars and Improving the Cosmetic Appearance of Scars: A Systematic Review and Meta-Analysis

Abstract

Background

Objective

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material